Naturally acquired cellular immune responses to the synthetic malarial peptide SPf66 in children in Papua New Guinea

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 91, Issue 6, 1997, Pages 709-712

  Al Yaman, F ^a,b   Genton, B ^a   Taraika, J ^a   Alpers, M P ^a  

^a PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Cellular immunity; Interferon ; Interleukin 4; Malaria; Papua New Guinea; Plasmodium falciparum; SPf66

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; MALARIA VACCINE; SYNTHETIC PEPTIDE;

ADOLESCENT; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CHILD; CLINICAL TRIAL; DRUG EFFICACY; HELPER CELL; HUMAN; INFANT; LONGITUDINAL STUDY; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALARIA; MORBIDITY; PAPUA NEW GUINEA;

PLASMODIUM FALCIPARUM; PROTOZOA; STAPHYLOCOCCUS PHAGE 187;

EID: 0031460940     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(97)90534-4     Document Type: Article

References (26)

1. Alonso, P. L., Smith, T., Armstrong Schellenberg, J. R. M., Masanja, H., Mwankusye, S., Urassa, H., Bastos de Azevedo, I., Chongela, J., Kobero, S., Menendez, C., Hurt, N., Thomas, M. C., Lyimo, E., Weiss, N. A., Hayes, R., Kitua, A. Y., Lopez, M. C., Kilama, W. L., Teuscher, T. & Tanner, M. (1994). Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet, 344, 1175-1182.
2. Alpers, M. P., Al-Yaman, F., Beck, H.-P., Bhatia, K. K., Hii, J., Lewis, D. J., Paru, R. & Smith, T. A. (1992). The malaria vaccine epidemiology and evaluation project of Papua New Guinea: rationale and baseline studies. Papua New Guinea Medical Journal, 35, 285-297.
3. Al-Yaman, F., Genton, B., Anders, R., Taraika, J., Ginny, M., Mellor, S. & Alpers, M. P. (1995). Assessment of the role of humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. Parasite Immunology, 17, 493-501.
4. Al-Yaman, F., Genton, B., Taraika, J., Anders, R. F. & Alpers, M. P. (in press). Association between cellular response (IL-4) to RESA/Pf155 and protection from clinical malaria among Papua New Guinean children living in a malaria endemic area. Parasite Immunology, 19.
5. Al-Yaman, F., Genton, B., Reeder, J. C., Anders, R. F., Smith, T. & Alpers, M. P. (1997). Reduced risk of clinical malaria in children infected with multiple clones of Plasmodium falciparum in a highly endemic area: a prospective community study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 91, 602-605.
6. Beck, H.-P., Felger, I., Kabintik, S., Tavul, L., Genton, B., Alexander, N., Bhatia, K. K., Al-Yaman, F., Hii, J. & Alpers, M. (1994). Assessment of the humoral and cell-mediaed immunity against the Plasmodium falciparum vaccine candidates circumsporozoite protein and SPf66 in adults living in a highly endemic malarious area of Papua New Guinea. American Journal of Tropical Medicine and Hygiene, 51, 356-364.
7. Beck, H.-P., Felger, I., Barker, M., Bugawan, T., Alexander, N., Jazwinska, E., Erlich, H. & Alpers, M. P. (1995). Evidence of HLA class II associated with antibody response against the malaria vaccine SPf66 in a naturally exposed population. American Journal of Tropical Medicine and Hygiene, 53, 284-288.
8. Beck, H.-P., Felger, I., Huber, W., Steiger, S., Smith, T.,Wiess, N., Alonso, P. & Tanner, M. (1997). Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66. Journal of Infectious Diseases, 175, 921-926.
9. Chang, S. P., Kramer, K. J.,Yamaga, K. M., Kato, A., Case, S. E. & Siddiqui, W. A. (1988). Plasmodium falciparum: gene structure and hydropathy profile of the major merozoite surface antigen (gp195) of the Uganda Palo Alto isolate. Experimental Parasitology, 67, 1-11.
10. D'Alessandro, U., Leach, A., Drakelcy, C. J., Bennct, S., Olaleye, B. O., Fegan, G. W., Jawara, M., Langerock, P., George, M. O., Targett, G. A. & Greenwood, B. M. (1995). Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet, 346, 462-467.
11. Genton, B., Al-Yaman, F., Beck, H.-P., Hii, J., Mellor, S., Narara, A., Gibson, N., Smith, T. & Alpers, M. P. (1995a). The epidemiology of malaria in the Wosera area, East Sepik province of Papua New Guinea, in preparation for vaccine trials. I. Malariometric indices and immunity. Annals of Tropical Medicine and Parasitology, 89, 359-376.
12. Genton, B., Al-Yaman, F., Beck, H.-P., Hii, J., Mellor, S., Rare, L., Ginny, M., Smith,T. & Alpers, M. P. (1995b). The epidemiology of malaria in the Wosera area, East Sepik province of Papua New Guinea, in preparation for vaccine trials. II. Mortality and morbidity. Annals of Tropical Medicine and Parasitology, 89, 377-390.
13. Kramer, K. J., Kan, S. C. & Siddiqui, W. A. (1982). Concentration of Plasmodium falciparum-infected erythrocytes by density gradient centrifugation in Percoll. Journal of Parasitology, 68, 336-337.
14. Millet, P., Campbell, G. H., Sulzer, A. J., Grady, K. K., Pohl, J., Aikawa, M. & Collins, W. E. (1993). Immunogenicity of the Plasmodium falciparum asexual blood-stage synthetic peptide vaccine SPf66. American Journal of Tropical Medicine and Hygiene, 48, 424-431.
15. Murillo, L. A.,Tenjo, F. A., Clavijo, O. P., Orozco, M. A., Sampaio, S., Kalil, J. & Patarroyo, M. E. (1992). A specific T-cell receptor genotype preference in the immune response to the synthetic Plasmodium falciparum malaria vaccine. Parasite Immunology, 14, 87-94.
16. Nosten, F., Luxemburger, C., Kyle, D. E., Ballou, R. W., Wittes, J.,Wah, E. H., Chongsuphajaisiddhi, T., Gordon, D., White, N. J., Sadoff, J. C. & Heppner, D. G. (1996). Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet, 348, 701-707.
17. Noya, O., Berti, Y. G., de Noya, B. A., Borges, R., Zerpa, N., Urbaez, J. D., Madonna, A., Garrido, E., Jimenez, M. A., Borges, R. E., Garcia, P., Reyes, I., Prieto, W., Colmenares, C., Pabon, R., Barraez, T., de Caceres, L. G., Godoy, N. & Sifontes, R. (1994). A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. Journal of Infectious Diseases, 170, 396-402.
18. Patarroyo, M. E., Amador, R., Clavijo, P., Moreno, A., Guzman, F., Romero, P., Tascon, R., Franco, A., Murillo, L. A., Ponton, G. & Truhillo, G. (1988). A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature, 332, 158-161.
19. Patarroyo, M. E., Vinasco, J., Amador, R., Espejo, F., Silva, Y., Moreno, A., Rojas, M., Mora, A. L., Salcedo, M., Valero, V., Goldeberg, A. K. & Kalil, J. (1991). Genetic control of the immune response to a synthetic vaccine against Plasmodium falciparum. Parasite Immunology, 13, 509-516.
20. Riley, E. M., Olerup, O. & Troy-Blomberg, M. (1991). The immune recognition of malaria antigens. Parasitology Today, 7, 5-11.
21. Rodriguez, R., Morena, A., Guzman, F., Calvo, M. & Patarroyo, M. E. (1990). Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 43, 339-354.
22. Ruebush, T. K., II, Campbell, G. H., Moreno, A., Patarroyo, M. E. & Collins, W. E. (1990). Immunization of owl monkeys with a combination of Plasmodium falciparum asexual blood-stage synthetic peptide antigens. American Journal of Tropical Medicine and Hygiene, 43, 355-366.
23. Sempertegui, F., Estrella, B., Moscoso, J., Piedrahita, L., Hernandez, D., Gaybor, J., Naranjo, P., Mancero, O., Arias, S., Bernal, R., Cordova, M. E., Suarez, J. & Zicker, F. (1994). Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine, 12, 337-342.
24. Targett, G. A. T. (1992). SPf66, a candidate synthetic malaria vaccine: immunogenicity versus protection. Parasitology Today, 8, 354-355.
25. Valero, M. V., Amador, L. R., Galindo, C., Figueroa, J., Bello, M. S., Murillo, L. A., Mora, A. L., Patarroyo, G., Rocha, C. L., Rojas, M., Aponte, J. J., Sarmiento, L. E., Lozada, D. M., Coronell, C. G., Ortega, N. M., Rosas, J. E., Alonso, P. L. & Patarroyo, M. E. (1993). Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet, 341, 705-710.
26. Valero, M. V., Amador, R., Aponte, J. J., Narvaez, A., Galindo, C., Silva, Y., Rosas, J., Guzman, F. & Patarroyo, M. E. (1997). Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial on the pacific coast of Columbia. Vaccine, 14, 1466-1470.